Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1,294 | $1,177 | $1,052 |
| Gross Profit | $0 | -$1,294 | -$1,177 | -$1,052 |
| % Margin | – | – | – | – |
| R&D Expenses | $83,231 | $54,047 | $47,849 | $37,720 |
| G&A Expenses | $20,799 | $20,798 | $20,826 | $18,926 |
| SG&A Expenses | $20,799 | $20,798 | $20,826 | $18,926 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$319 | -$189 |
| Operating Expenses | $104,030 | $75,645 | $68,675 | $56,646 |
| Operating Income | -$104,030 | -$75,645 | -$68,675 | -$56,646 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2,006 | $4,476 | $1,614 | $22 |
| Pre-Tax Income | -$102,024 | -$71,169 | -$67,061 | -$56,624 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$102,024 | -$71,169 | -$65,447 | -$56,413 |
| % Margin | – | – | – | – |
| EPS | -1.62 | -1.37 | -1.73 | -2.39 |
| % Growth | -18.2% | 20.8% | 27.6% | – |
| EPS Diluted | -1.62 | -1.37 | -1.73 | -2.39 |
| Weighted Avg Shares Out | 62,812 | 51,839 | 37,763 | 23,558 |
| Weighted Avg Shares Out Dil | 62,812 | 51,839 | 37,763 | 23,558 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,666 | $7,837 | $1,933 | $211 |
| Interest Expense | -$5,558 | $3,333 | $0 | $0 |
| Depreciation & Amortization | $3,552 | $833 | $1,177 | $1,052 |
| EBITDA | -$104,030 | -$74,812 | -$65,884 | -$55,972 |
| % Margin | – | – | – | – |